Sysmex (OTCMKTS:SSMXY) Corporation (OTCMKTS:SSMXY) is a Japan‐based provider of medical diagnostic equipment and laboratory information systems. Specializing in in vitro diagnostics, the company develops, manufactures and sells systems for hematology, hemostasis, urinalysis, immunochemistry and molecular diagnostics. Its product portfolio ranges from fully automated blood cell counters and coagulation analyzers to specialized reagents, software platforms and remote monitoring tools designed to enhance workflow efficiency in clinical laboratories.
Established in 1968 and headquartered in Kobe, Japan, Sysmex has built a reputation for integrating advanced biotechnology with digital solutions. The company’s automated hematology systems enable high‐throughput analysis of blood cell parameters, while its molecular diagnostics offerings support applications such as infectious disease screening and genetic testing. Sysmex also provides laboratory information management systems (LIMS) that streamline data handling and quality control procedures, helping laboratory professionals maintain regulatory compliance and improve diagnostic turnaround times.
Operating through a network of subsidiaries and distributors, Sysmex serves healthcare providers, research institutions and public health laboratories in more than 190 countries. Major regional units include Sysmex America, Sysmex Europe and Sysmex Asia Pacific, each responsible for local sales, service support and regulatory affairs. This global footprint is complemented by strategic partnerships with hospitals, diagnostic laboratories and academic centers, underscoring Sysmex’s commitment to advancing healthcare delivery on multiple continents.
Governed by an executive leadership team led by the President and Chief Executive Officer, Sysmex emphasizes research and development as a core growth driver. The company invests heavily in innovation, holding numerous patents in hematology and molecular technologies and collaborating with universities and industry partners. With a focus on quality management and sustainable business practices, Sysmex continues to expand its diagnostic capabilities while supporting initiatives in digital pathology and personalized medicine.
